The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Shares of Kenvue rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company’s Chief Financial Officer, effective ...

(Reuters) -Kenvue beat quarterly profit and revenue estimates on Thursday as better-than-expected demand for cough-and-cold ...

This was the stock's third consecutive day of losses.

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

Kenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the ...

Kenvue ( NYSE: KVUE) has appointed Amit Banati as the company’s next chief financial officer, effective May 12, 2025. Tariffs are triggering volatility. Don’t wait for tomorrow’s headlines—get the ...